Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 988 participants.

Also called NCT07405671

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 988 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07405671
  • EudraCT 2025-525121-13
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07405671. Randomized; no masking; primary purpose treatment. Start 2026-09 (anticipated); primary completion 2029-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation
Acronym
ReCAST AF
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
flecainide
Intervention (Drug)
Sotalol or Amiodarone
Lead sponsor
Universitaire Ziekenhuizen KU Leuven (class: other)
Collaborator
Research Foundation Flanders (class: other)

Record details

Record id
cardio:ct-nct07405671
Content hash
24fd0cf5757c5a3812b36e6992b6c9804ee1605066146dffe93faf64b695b7fd